Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,015 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Abou-Alfa GK, et al. Among authors: santoro a. J Clin Oncol. 2006 Sep 10;24(26):4293-300. doi: 10.1200/JCO.2005.01.3441. Epub 2006 Aug 14. J Clin Oncol. 2006. PMID: 16908937 Clinical Trial.
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: santoro a. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Free article. Clinical Trial.
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Bruix J, et al. Among authors: santoro a. J Hepatol. 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014. Epub 2012 Jun 19. J Hepatol. 2012. PMID: 22727733 Free article. Clinical Trial.
Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D, Frassineti GL, De Matteis A, Mustacchi G, Santoro A, Cariello S, Ferrari M, Nascimben O, Nanni O, Lombardi A, Scarpi E, Zoli W. Amadori D, et al. Among authors: santoro a. Breast Cancer Res Treat. 1998 Jun;49(3):209-17. doi: 10.1023/a:1006063412726. Breast Cancer Res Treat. 1998. PMID: 9776504 Clinical Trial.
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17. Br J Cancer. 2010. PMID: 20717115 Free PMC article. Clinical Trial.
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A. Pressiani T, et al. Among authors: santoro a. Ann Oncol. 2013 Feb;24(2):406-411. doi: 10.1093/annonc/mds343. Epub 2012 Oct 5. Ann Oncol. 2013. PMID: 23041587 Free article. Clinical Trial.
3,015 results